Cancer Stem Cells Persist Despite Cellular Damage, Emergence of the Refractory Cell Population

PURPOSE: Cancer stem cells (CSCs) are responsible for chemotherapy resistance and have unique properties that protect them from chemotherapy. Investigating CSCs may help to identify the population that is more resistant to treatments, leading to recurrence. We evaluated persisting CSCs, emerging aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagae, Ayumi, Miyoshi, Norikatsu, Fujino, Shiki, Horie, Masafumi, Yachida, Shinichi, Sasaki, Masaru, Sekido, Yuki, Hata, Tsuyoshi, Hamabe, Atsushi, Ogino, Takayuki, Takahashi, Hidekazu, Uemura, Mamoru, Yamamoto, Hirofumi, Doki, Yuichiro, Eguchi, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506944/
https://www.ncbi.nlm.nih.gov/pubmed/37523119
http://dx.doi.org/10.1245/s10434-023-13849-x
Descripción
Sumario:PURPOSE: Cancer stem cells (CSCs) are responsible for chemotherapy resistance and have unique properties that protect them from chemotherapy. Investigating CSCs may help to identify the population that is more resistant to treatments, leading to recurrence. We evaluated persisting CSCs, emerging after chemotherapy that cause tumor recurrence. METHODS: Using human colorectal cancer organoids prepared from surgical specimens, we looked at changes in CSCs, the emergence and changes in the original population, which single-cell analysis identified. RESULTS: With regards to changes in cancer stem cell markers, CD44 showed low levels after 5-fluorouracil administration. Once the CD44-ve population was sorted and cultured, the CD44+ve population gradually emerged, and the CD44-ve population decreased. Compared with the CD44-ve population of an organoid parent, the CD44-ve population proliferated after chemotherapeutic agent stimulation. The CD44-ve population was derived from the CD44+ve population before chemotherapeutic agents. In addition, when the CD44 variants were evaluated, the CD44v9 population remained. In single-cell analysis, we found that POU5F1 was highly expressed in the CD44low population. Velocity analysis showed that the CD44-ve population was induced after chemotherapy and expressed POU5F1. POU5F1-EGFP-Casp9 transfected organoids resulted in the appearance of a CD44-ve population after administration of a chemotherapeutic reagent. Both in vivo and in vitro, the dimerizer administration inhibited tumor growth significantly. CONCLUSIONS: POU5F1 is involved in chemotherapy resistance in relation to stemness. For the treatment against refractory tumors, such as the recurrence after chemotherapy, the treatment should target the emerging specific population such as CD44 (or CD44v9) and proliferative cancer cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-023-13849-x.

Ejemplares similares